[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549192":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":22,"locations":32,"responsibleParty":79,"collaborators":81,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":10,"eligibilityCriteria":93,"healthyVolunteers":90,"sex":94,"minAge":95,"maxAge":10,"enrollmentInfo":96,"targetDuration":10,"studyType":99,"phases":10,"briefSummary":100,"conditions":101,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University of Southern Denmark","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Breastcancer patients",null,"A total of 188 patients diagnosed with breast cancer who are scheduled for paclitaxel treatment, either as adjuvant or neo-adjuvant treatment, will be recruited across three trial sites.",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No intervention",[9],[19],{"name":20,"affiliation":5,"role":21},"Ditte Bork Iversen","STUDY_CHAIR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Ditte Bork Iversen, MSc Pharm, PhD","CONTACT","+45 65 50 23 52","dbiversen@health.sdu.dk",{"name":29,"role":25,"phone":30,"phoneExt":10,"email":31},"Tore B. Stage, Prof","+45 65 50 36 78","tstage@health.sdu.dk",[33,51,65],{"facility":34,"status":35,"city":36,"state":10,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Odense University Hospital","RECRUITING","Odense","5000","Denmark","DK",{"type":41,"coordinates":42},"Point",[43,44],10.38831,55.39594,{"lat":44,"lon":43},[47],{"name":48,"role":25,"phone":49,"phoneExt":10,"email":50},"Marianne Vogsen","+4550932282","marianne.vogsen@rsyd.dk",{"facility":52,"status":35,"city":53,"state":10,"zip":54,"country":38,"countryCode":39,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"University Hospital of Southern Denmark, Sønderborg","Sønderborg","6400",{"type":41,"coordinates":56},[57,58],9.78917,54.90896,{"lat":58,"lon":57},[61],{"name":62,"role":25,"phone":63,"phoneExt":10,"email":64},"Marianne Christensen","+4579973034","marianne.christensen.onk@rsyd.dk",{"facility":66,"status":35,"city":67,"state":10,"zip":68,"country":38,"countryCode":39,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"University Hospital of Southern Denmark, Vejle","Vejle","7100",{"type":41,"coordinates":70},[71,72],9.5357,55.70927,{"lat":72,"lon":71},[75],{"name":76,"role":25,"phone":77,"phoneExt":10,"email":78},"Lise Ventzel","+4579406060","lise.ventzel@rsyd.dk",{"type":80,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[82,83,85],{"name":34,"class":6},{"name":84,"class":6},"Sygehus Lillebaelt",{"name":86,"class":87},"Sonderborg Hospital","OTHER_GOV","100549192","clinical-biomarker-of-paclitaxel-induced-peripheral-neuropathy-100549192",false,"NCT06430814","Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Age \\> 18 years\n* Willing to give informed consent\n* Scheduled to receive neo-adjuvant or adjuvant paclitaxel treatment\n* Able to speak and understand Danish\n* Diagnosed with breast cancer\n* Paclitaxel naïve patients\n\nExclusion Criteria:\n\n* Neurodegenerative diseases (e.g., neuropathy from another cause, previous apoplexy, disc herniation\n* Type 1 or 2 diabetes\n* Pregnant\n* Breastfeeding\n* Relapse of cancer diagnosis\n* Diagnosed with human immunodeficiency virus (HIV)\n* Participation in other clinical trials where the dose of paclitaxel is changed, or the aim is to prevent neuropathic pain or decrease NFL level (except if the intervention is to use cooling gloves).\n* Previous treatment with neurotoxic chemotherapy\n* Chronic pain from another cause\n* Metastatic cancer","FEMALE","18 Years",{"count":97,"type":98},188,"ESTIMATED","OBSERVATIONAL","Investigation of which patients treated with paclitaxel have an increased risk of developing peripheral neuropathy.",[102],"Chemotherapy-induced Peripheral Neuropathy","2025-08-25",{"date":105,"type":106},"2025-09-02","ACTUAL",{"date":108,"type":106},"2024-10-10",{"date":110,"type":98},"2027-09",{"name":5,"class":6},3]